
Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

Your AI-Trained Oncology Knowledge Connection!


Pankit Vachhani, MD, is an associate professor of medicine and associate scientist of experimental therapeutics at the University of Alabama at Birmingham.

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.